Abstract
Estrogen receptor α (ERα) is a transcription factor that regulates expression of target genes in a ligand-dependent manner. Activation of gene expression is mediated by two transcription activation functions AF-1 and AF-2, which act in a promoter- and cell-specific manner. Whilst AF-2 activity is regulated by estrogen (E2) binding, the activity of AF-1 is additionally modulated by phosphorylation at several sites. One of these phosphorylation sites, serine 118 (S118) is of particular interest as its mutation significantly reduces ERα activity. Previous studies have shown that S118 can be phosphorylated by the ERK1/2 mitogen activated protein kinases (MAPK) and by the cyclin-dependent protein kinase Cdk7. In this study we use antisera that specifically recognize ERα phosphorylated at S118 to demonstrate that MAPK phosphorylates S118 in a ligand-independent manner, whereas Cdk7 mediates E2-induced phosphorylation of S118. E2 stimulation of S118 phosphorylation was observed within 10 min of its addition and was maximal at 10−7 M E2. S118 phosphorylation was maximal at 30 min but then declined, such that by 180 min following E2 addition little S118 phosphorylation was evident. S118 phosphorylation was also induced by the partial estrogen antagonist 4-hydroxytamoxifen, but not by the complete antagonist ICI 182, 780. S118 phosphorylation upon addition of the MAPK inducers EGF or PMA followed the expected time courses. Finally, we show that ERα is phosphorylated at S118 in vivo using immunoblotting of extracts prepared from a series of ERα-positive breast tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Saito Y, Campbell DG, Cohen P, Sithanandam G, Rapp U, Ashworth A, Marshall CJ, Cowley S . 1994 EMBO J. 13: 1610–1619
Alessi DR, Smythe C, Keyse SM . 1993 Oncogene 8: 2015–2020
Ali S, Coombes RC . 2000 J. Mamm. Gland Biol. Neoplasia 5: 271–281
Ali S, Lutz Y, Bellocq J-P, Chenard-Neu M-P, Rouyer N, Metzger D . 1993a Hybridoma 12: 391–405
Ali S, Metzger D, Bornert JM, Chambon P . 1993b EMBO J. 12: 1153–1160
Arnold SF, Obourn JD, Jaffe H, Notides AC . 1994 Mol. Endocrinol. 8: 1208–1214
Arnold SF, Obourn JD, Jaffe H, Notides AC . 1995 J. Steroid Biochem. Mol. Biol. 55: 163–172
Barettino D, Vivanco Ruiz MM, Stunnenberg HG . 1994 EMBO J. 13: 3039–3049
Beato M, Herrlich P, Schutz G . 1995 Cell 83: 851–857
Berry M, Metzger D, Chambon P . 1990 EMBO J. 9: 2811–2818
Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS . 1986 Proc. Natl. Acad. Sci. USA 83: 2496–2500
Blumberg B, Evans RM . 1998 Genes Dev. 12: 3149–3155
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M . 1997 Nature 389: 753–758
Bunone G, Briand PA, Miksicek RJ, Picard D . 1996 EMBO J. 15: 2174–2183
Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, Ali S . 2000 Mol. Cell 6: 127–137
Couse, Korach KS . 1999 Endocr. Rev. 20: 358–417
Coutts AS, Murphy LC . 1998 Cancer Res. 58: 4071–4074
Danielian PS, White R, Lees JA, Parker MG . 1992 EMBO J. 11: 1025–1033
Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P . 1994 EMBO J. 13: 5370–5382
Gee JM, Robertson JF, Ellis IO, Nicholson RI . 2001 Int. J. Cancer 95: 247–254
Glass CK, Rosenfeld MG . 2000 Genes Dev. 14: 121–141
Gonzalez FA, Raden DL, Davis RJ . 1991 J. Biol. Chem. 266: 22159–22163
Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P . 1986 Nature 320: 134–139
Gronemeyer H . 1991 Annu. Rev. Genet. 25: 89–123
Horwitz KB . 1994 J. Steroid Biochem. Mol. Biol. 49: 295–302
Horwitz KB, Koseki Y, McGuire WL . 1978 Endocrinology 103: 1742–1751
Howe LR, Leevers SJ, Gomez N, Nakielny S, Cohen P, Marshall CJ . 1992 Cell 71: 335–342
Joel PB, Traish AM, Lannigan DA . 1998 J. Biol. Chem. 273: 13317–13323
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P . 1995 Science 270: 1491–1494
Keyse SM, Emslie EA . 1992 Nature 359: 644–647
Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D, Yanagisawa J, Kato S . 2000 J. Biol. Chem. 275: 15645–15651
Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS . 1994 J. Biol. Chem. 269: 4458–4466
Lees JA, Fawell SE, Parker MG . 1989 Nucleic Acids Res. 17: 5477–5488
Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B . 1999 Science 284: 1362–1365
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM . 1995 Cell 83: 835–839
McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW . 1995 Mol. Endocrinol. 9: 659–669
McGuire WL . 1978 Semin. Oncol. 5: 428–433
Metzger D, Ali S, Bornert JM, Chambon P . 1995a J. Biol. Chem. 270: 9535–9542
Metzger D, Berry M, Ali S, Chambon P . 1995b Mol. Endocrinol. 9: 579–591
Moras D, Gronemeyer H . 1998 Curr. Opin. Cell. Biol. 10: 384–391
Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM . 1999 Science 284: 1365–1368
Robertson JF . 1996 Br. J. Cancer 73: 5–12
Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH . 1998 Curr. Biol. 8: 1141–1150
Rogatsky I, Trowbridge JM, Garabedian MJ . 1999 J. Biol. Chem. 274: 22296–22302
Saatcioglu F, Bartunek P, Deng T, Zenke M, Karin M . 1993 Mol. Cell. Biol. 13: 3675–3685
Shao D, Lazar MA . 1999 J. Clin. Invest. 103: 1617–1618
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL . 1998 Cell 95: 927–937
Sivaraman VS, Wang H, Nuovo GJ, Malbon CC . 1997 J. Clin. Invest. 99: 1478–1483
Smith CL . 1998 Biol. Reprod. 58: 627–632
Tassan JP, Schultz SJ, Bartek J, Nigg EA . 1994 J. Cell. Biol. 127: 467–478
Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P . 1989a EMBO J. 8: 1981–1986
Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P . 1989b Cell 59: 477–487
Tsai MJ, O'Malley BW . 1994 Annu. Rev. Biochem. 63: 451–486
Wang H, Chen J, Hollister K, Sowers LC, Forman BM . 1999 Mol. Cell. 3: 543–553
Webster NJ, Green S, Jin JR, Chambon P . 1988 Cell 54: 199–207
Yankulov K, Yamashita K, Roy R, Egly JM, Bentley DL . 1995 J. Biol. Chem. 270: 23922–23925
Acknowledgements
We are grateful to Prof Pierre Chambon and Dr Daniel Metzger for the ER plasmids and for expression vectors. We would also like to thank Prof Chris Marshall for providing purified ERK2 protein and plasmids and for helpful discussions. Our thanks also go to Drs S Keyse, E Nigg, T Makela, DO Morgan, G Peters and MH Cobb. For technical help we thank Xiaomei Ouyang. This work was supported by the Cancer Research UK and the Mandeville Trust.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, D., Washbrook, E., Sarwar, N. et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21, 4921–4931 (2002). https://doi.org/10.1038/sj.onc.1205420
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205420
Keywords
This article is cited by
-
Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer
British Journal of Cancer (2024)
-
Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
Cellular and Molecular Life Sciences (2023)
-
A novel culture method that sustains ERα signaling in human breast cancer tissue microstructures
Journal of Experimental & Clinical Cancer Research (2020)
-
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Oncogene (2020)
-
CDK7 inhibitors as anticancer drugs
Cancer and Metastasis Reviews (2020)